Based on the updated response rate and maturing durability data, as well as having been awarded FDA Fast Track Designation for DLBCL in March 2025, Imugene will request a Type B (End of Phase 1) ...

A genetically diverse mouse model allowed researchers to identify genes that promote the success of immune checkpoint ...

Imugene is tapping the market for up to $35 million, while Clever Culture Systems and Compumedics are soaring on positive ...

Nurix Therapeutics shows strong BTK degrader data and key pharma ties, with risks but solid long-term potential. Find out why ...

ALZHEIMER’S disease (AD), a neurodegenerative condition marked by cognitive decline and progressive memory loss, has long been associated with chronic inflammation and immune dysregulation. Regulatory ...

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

A new study published in Brain Research suggests that adding okra to the diet can protect against long-term metabolic problems caused by early-life overfeeding. In a rat model, okra supplementation ...

The trial is spearheaded by Dr Jonathan Hernandez, the surgical oncology section chief of the National Cancer Institute.

Sarilumab treatment with a rapid glucocorticoid taper in relapsing polymyalgia rheumatica shows greater improvements in ...

Pacira BioSciences Inc. (NASDAQ:PCRX) is one of the most undervalued small-cap stocks to buy according to analysts.

Treatment with dupilumab is associated with weight gain in about two thirds of adults with atopic dermatitis over 3-6 months, according to a retrospective study.